Top Tech Companies (766)
Don't see your company?
Create a company profile
Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis (LN). Aurinia’s head office is in Victoria, British Columbia; its U.S. commercial hub is in Rockville, Maryland; and the Company focuses development efforts globally. Follow us on Twitter at @AuriniaPharma and on LinkedIn.
RD Laboratories, Inc. is a privately held, independent contract-testing laboratory specializing in pharmaceutical services. Founded in 1984 by Richard E. Ritz, RD Laboratories provides prompt and accurate pharmaceutical testing with a focus on personalized customer service. Still owned and operated today by the Ritz family, RD Laboratories remains true to Mr. Ritz’s forward focused vision of a specialized laboratory built on the three pillars of accuracy, promptness and competitiveness. RD Laboratories continues to invest heavily in technology that reflects the latest scientific advances in testing methods and instrumentation. Our modern, cGMP compliant facility just 45 minutes from downtown Saint Louis is staffed by a knowledgeable, highly-trained team of professionals who are focused on providing the dependable turnaround and accurate test results that are our hallmark. Our customers have come to expect the reliable communication, professional expertise and attention to detail that flow from our emphasis on the development of straightforward and efficient internal protocols and direct access to laboratory management and trained office personnel. We welcome you to contact RD Laboratories today to learn more about how we get results for our customers.
Enriching Lives Through Personalized Medicine and Care Doing the right thing... in the right way... at the right time... in the right place... for the right person... with the right feeling... the first time. Akina Specialty Compounding Pharmacy is purpose driven to provide healthcare providers and their patients with the most meticulously sterile and non-sterile compounded medications and exceptional service.
Prevacus is a drug development company working on the prevention and treatment of mild traumatic brain injury (mTBI) or concussion.
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies.
AmbioPharm, a global peptide CDMO, was founded in 2005 and is headquartered in North Augusta, South Carolina, USA specializing in developing highly efficient manufacturing processes for peptide-based Active Pharmaceutical Ingredients (APIs) at very small to very large scales. In our manufacturing facilities in South Carolina, USA and Shanghai, China, we manufacture New Chemical Entities (NCEs) and generic peptide APIs under cGMP for clients worldwide. Both facilities have been inspected multiple times by the FDA with excellent outcomes. Ambio is a drug development company with a rich and growing pipeline of proprietary drug development programs for bioequivalent and biosimilar versions of the world’s best-selling peptide drugs. Ambio Pharmaceuticals is the parent company of AmbioPharm, Inc. and Ambio, Inc.
Capsule is rebuilding the $425 billion pharmacy industry from the inside out with an emotionally resonant brand and technology that enables customized outcomes for doctors, hospitals, insurers, and manufacturers. Our team makes the same promise to each other as the one we’ve made to our customers, doctors, and partners: everybody needs some looking after sometimes. We’ll never lose sight of the fact that behind all the craziness of the healthcare system, we’re just people looking after other people. Capsule has raised over $500MM from the best healthcare and technology investors in the world.
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com. Community Guidelines: http://bit.ly/ArvinasCG
Elevar Therapeutics is a pharmaceutical company that specializes in the development of therapies for unmet medical needs in cancer.
RxSolutions is a company that specializes in customized pharmaceutical reimbursement programs.
.jpeg)
.png)
Temperatsure, LLC manufactures gel packs and enables cold chain logistics solutions for the pharmaceutical and food industries.
Arbor Pharmaceuticals is a specialty pharmaceutical company developing late-stage therapeutic products for common pediatric conditions.
Mixlab is the first modern, tech-enabled pet pharmacy that focuses on creating custom medications and delightful experiences for pets, their parents and veterinarians. By putting service at the heart of everything we do, our talented team is able to provide the best personalized care for our patients, as well as those who care for them.
Summit Biosciences is developing, manufacturing & commercializing generic and innovative nasal spray drug products.
Jenrin Discovery is a biopharmaceutical Company.
Imricor Medical Systems develops magnetic resonance imaging compatible electrophysiology tools for the treatment of cardiac arrhythmias.
Scholar Rock is a biopharmaceutical company that discovers, develops, and delivers life-changing therapies for people with serious diseases that have high unmet need. As a global leader in the biology of the transforming growth factor beta (TGFβ) superfamily of cell proteins and named for the visual resemblance of a scholar rock to protein structures, the clinical-stage company is focused on advancing innovative treatments where protein growth factors are fundamental. Over the past decade, the company has created a pipeline with the potential to advance the standard of care for neuromuscular disease, cardiometabolic disorders, cancer, and other conditions where growth factor-targeted drugs can play a transformational role. Scholar Rock is the only company to show clinical proof of concept for a muscle-targeted treatment in spinal muscular atrophy (SMA). This commitment to unlocking fundamentally different therapeutic approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. By harnessing cutting-edge science in disease spaces that are historically under-addressed through traditional therapies, Scholar Rock works every day to create new possibilities for patients. Learn more about the company’s approach at ScholarRock.com and follow @ScholarRock and on LinkedIn. For additional information on our guidelines, please visit https://scholarrock.com/community-guidelines/ For more information on how Scholar Rock collects, uses, and shares personal information, please visit: https://scholarrock.com/privacy-policy
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.
Laker Software is claims processing systems and support services. The company provides its services for prescription drug benefit programs.
Tandem Labs is a leading bioanalytical Contract Research Organization (CRO) specializing in advanced mass spectrometry.
